231 related articles for article (PubMed ID: 35190267)
1. Characterizing human mesenchymal stromal cells' immune-modulatory potency using targeted lipidomic profiling of sphingolipids.
DeVeaux SA; Ogle ME; Vyshnya S; Chiappa NF; Leitmann B; Rudy R; Day A; Mortensen LJ; Kurtzberg J; Roy K; Botchwey EA
Cytotherapy; 2022 Jun; 24(6):608-618. PubMed ID: 35190267
[TBL] [Abstract][Full Text] [Related]
2. Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues.
Fazzina R; Iudicone P; Fioravanti D; Bonanno G; Totta P; Zizzari IG; Pierelli L
Stem Cell Res Ther; 2016 Aug; 7(1):122. PubMed ID: 27557940
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Mesenchymal Stromal Cells Isolated from Murine Adipose Tissue and Bone Marrow in the Treatment of Spinal Cord Injury.
Takahashi A; Nakajima H; Uchida K; Takeura N; Honjoh K; Watanabe S; Kitade M; Kokubo Y; Johnson WEB; Matsumine A
Cell Transplant; 2018 Jul; 27(7):1126-1139. PubMed ID: 29947256
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive characterisation of large-scale expanded human bone marrow and umbilical cord mesenchymal stem cells.
Mennan C; Garcia J; Roberts S; Hulme C; Wright K
Stem Cell Res Ther; 2019 Mar; 10(1):99. PubMed ID: 30885254
[TBL] [Abstract][Full Text] [Related]
5. Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions.
Thirlwell KL; Colligan D; Mountford JC; Samuel K; Bailey L; Cuesta-Gomez N; Hewit KD; Kelly CJ; West CC; McGowan NWA; Casey JJ; Graham GJ; Turner ML; Forbes S; Campbell JDM
Cytotherapy; 2020 Dec; 22(12):762-771. PubMed ID: 32828673
[TBL] [Abstract][Full Text] [Related]
6. Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach.
Calcat-I-Cervera S; Rendra E; Scaccia E; Amadeo F; Hanson V; Wilm B; Murray P; O'Brien T; Taylor A; Bieback K
Stem Cell Res Ther; 2023 May; 14(1):120. PubMed ID: 37143116
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human mesenchymal stem cells derived from dental pulp, bone marrow, adipose tissue, and umbilical cord tissue by gene expression.
Stanko P; Kaiserova K; Altanerova V; Altaner C
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):373-7. PubMed ID: 24145770
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy.
Wang Q; Yang Q; Wang Z; Tong H; Ma L; Zhang Y; Shan F; Meng Y; Yuan Z
Hum Vaccin Immunother; 2016; 12(1):85-96. PubMed ID: 26186552
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.
Batsali AK; Pontikoglou C; Koutroulakis D; Pavlaki KI; Damianaki A; Mavroudi I; Alpantaki K; Kouvidi E; Kontakis G; Papadaki HA
Stem Cell Res Ther; 2017 Apr; 8(1):102. PubMed ID: 28446235
[TBL] [Abstract][Full Text] [Related]
10. Characterization and Immunomodulatory Effects of Canine Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stromal Cells.
Russell KA; Chow NH; Dukoff D; Gibson TW; LaMarre J; Betts DH; Koch TG
PLoS One; 2016; 11(12):e0167442. PubMed ID: 27907211
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor.
Valencia J; Blanco B; Yáñez R; Vázquez M; Herrero Sánchez C; Fernández-García M; Rodríguez Serrano C; Pescador D; Blanco JF; Hernando-Rodríguez M; Sánchez-Guijo F; Lamana ML; Segovia JC; Vicente Á; Del Cañizo C; Zapata AG
Cytotherapy; 2016 Oct; 18(10):1297-311. PubMed ID: 27637760
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic Heterogeneity of Human Mesenchymal Stem Cells Derived from Bone Marrow, Dental Pulp, Adipose Tissue, and Umbilical Cord.
Zhu X; Xu X; Shen M; Wang Y; Zheng T; Li H; Wang X; Meng J
Cell Reprogram; 2023 Aug; 25(4):162-170. PubMed ID: 37384924
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics and cytokine profiling of mesenchymal stromal cells identify markers predictive of T-cell suppression.
Maughon TS; Shen X; Huang D; Michael AOA; Shockey WA; Andrews SH; McRae JM; Platt MO; Fernández FM; Edison AS; Stice SL; Marklein RA
Cytotherapy; 2022 Feb; 24(2):137-148. PubMed ID: 34696960
[TBL] [Abstract][Full Text] [Related]
14. Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells.
Kouroupis D; Bowles AC; Greif DN; Leñero C; Best TM; Kaplan LD; Correa D
Cytotherapy; 2020 Nov; 22(11):677-689. PubMed ID: 32723596
[TBL] [Abstract][Full Text] [Related]
15. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue.
Rebelatto CK; Aguiar AM; Moretão MP; Senegaglia AC; Hansen P; Barchiki F; Oliveira J; Martins J; Kuligovski C; Mansur F; Christofis A; Amaral VF; Brofman PS; Goldenberg S; Nakao LS; Correa A
Exp Biol Med (Maywood); 2008 Jul; 233(7):901-13. PubMed ID: 18445775
[TBL] [Abstract][Full Text] [Related]
16. Standardized xeno- and serum-free culture platform enables large-scale expansion of high-quality mesenchymal stem/stromal cells from perinatal and adult tissue sources.
Hoang VT; Trinh QM; Phuong DTM; Bui HTH; Hang LM; Ngan NTH; Anh NTT; Nhi PY; Nhung TTH; Lien HT; Nguyen TD; Thanh LN; Hoang DM
Cytotherapy; 2021 Jan; 23(1):88-99. PubMed ID: 33097415
[TBL] [Abstract][Full Text] [Related]
17. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue.
Heo JS; Choi Y; Kim HS; Kim HO
Int J Mol Med; 2016 Jan; 37(1):115-25. PubMed ID: 26719857
[TBL] [Abstract][Full Text] [Related]
18. Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells.
Guan Q; Li Y; Shpiruk T; Bhagwat S; Wall DA
Cytotherapy; 2018 May; 20(5):639-649. PubMed ID: 29548707
[TBL] [Abstract][Full Text] [Related]
19. Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis.
Yu Y; Yoo SM; Park HH; Baek SY; Kim YJ; Lee S; Kim YL; Seo KW; Kang KS
J Tissue Eng Regen Med; 2019 Oct; 13(10):1792-1804. PubMed ID: 31293088
[TBL] [Abstract][Full Text] [Related]
20. RIA fractions contain mesenchymal stroma cells with high osteogenic potency.
Kuehlfluck P; Moghaddam A; Helbig L; Child C; Wildemann B; Schmidmaier G;
Injury; 2015 Dec; 46 Suppl 8():S23-32. PubMed ID: 26747914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
